Updated:
Dermata Therapeutics, Inc.
Dermata Therapeutics is a dermatological drug development firm operating as a single-asset vehicle — no management team disclosed, no AUM reported.
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. emerged from public filings as a corporate entity, but no founder, founding year, or wealth origin is publicly documented. The firm's sole disclosed focus is dermatological therapeutics, with a single drug candidate (DMT-01) referenced in regulatory filings and clinical trial registries. The firm's strategy concentrates on advancing this compound through Phase I/II trials for conditions including acne vulgaris and rosacea, relying on external capital raises rather than an existing asset pool. No asset-class mix, fund structure, or co-investment relationships have been disclosed, and the firm's geographic footprint — if any — is unstated. Dermata has no known team size, additional offices, adjacent vehicles, or philanthropic structures. The last 24 months have produced no operational events beyond routine SEC filings and a small public offering of common stock in November 2024 (per SEC filings, Q4 2024). The firm's structural differentiator is its singularity: it functions as a single-asset vehicle with no diversification, no management team publicly identified, and no track record of capital deployment beyond R&D. This architecture is closer to a shell company than to a typical biotech fund or family office.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is Dermata Therapeutics' investment strategy?
Dermata Therapeutics does not operate as an allocator; its sole activity appears to be advancing DMT-01, a drug candidate for acne and rosacea, through clinical trials. No investment strategy, portfolio mix, or fund structure has been disclosed (per public filings).
Who manages Dermata Therapeutics?
No named management team or investment professionals are publicly linked to Dermata Therapeutics. The firm's SEC filings list only a corporate officer, but no investment decision-maker is identified (per SEC records).
Does Dermata Therapeutics make direct investments or deploy capital externally?
No. The firm's sole use of capital is internal R&D spending on DMT-01. It has no publicly recorded direct investments, co-investments, or external GP commitments (public record).
What is Dermata Therapeutics' relationship to the broader Altss dataset?
Dermata Therapeutics is included in the Altss coverage universe as a corporate entity categorized under Asset Manager, though it does not function as an allocator. Its presence reflects broad coverage of firms that may intersect with family office capital, but no family office link has been established.
How is Dermata Therapeutics different from a typical biotech fund?
A standard biotech fund diversifies across multiple portfolio companies or stages. Dermata Therapeutics holds a single asset, has no disclosed management team, and has no track record of capital deployment beyond its own R&D budget — it resembles a development-stage shell more than a fund.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: